Suchen
Halozyme Therapeutics Inc
HALOZur Watchlist hinzufügen
82.540USD
-0.760-0.91%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
9.78BMarktkapitalisierung
27.92KGV TTM
mehr Informationen über Halozyme Therapeutics Inc Unternehmen
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme Therapeutics Inc Informationen
BörsenkürzelHALO
Name des UnternehmensHalozyme Therapeutics Inc
IPO-datumJan 30, 2003
CEOTorley (Helen I)
Anzahl der mitarbeiter350
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
Addresse12390 El Camino Real
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92130
Telefon18587948889
Websitehttps://www.halozyme.com/
BörsenkürzelHALO
IPO-datumJan 30, 2003
CEOTorley (Helen I)
Führungskräfte von Halozyme Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
767.78K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
77.83K
+4.88%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
38.49K
--
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.05K
-103.63%
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Ms. Barbara Duncan
Ms. Barbara Duncan
Independent Director
Independent Director
--
--
Ms. Tram Bui
Ms. Tram Bui
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
767.78K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
77.83K
+4.88%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
38.49K
--
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.05K
-103.63%
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Halozyme Therapeutics Inc?
Die fünf größten Anteilseigner von Halozyme Therapeutics Inc sind: Dr. Helen I. Torley
Wie viele Institutionen halten Anteile an Halozyme Therapeutics Inc (HALO)?
Mit Stand vom 2026Q1 halten 1232 Institutionen Anteile an Halozyme Therapeutics Inc, mit einem Gesamtmarktwert von etwa 138.78M, was 117.14% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 5105303.00 gestiegen.
Was ist die größte Einnahmequelle von Halozyme Therapeutics Inc?
Am 2026Q1 erzielte das Geschäft mit Royalties für Halozyme Therapeutics Inc den höchsten Umsatz in Höhe von 867.84M, was 62.14% des Gesamtumsatzes entspricht.